Neoadjuvant therapy in elderly patients receiving FOLFIRINOX or gemcitabine/nab-paclitaxel for borderline resectable or locally advanced pancreatic cancer is feasible and lead to a similar oncological outcome compared to non-aged patients – Results of the RESPECT-Study
- Resource Type
- Article
- Source
- Surgical Oncology; December 2020, Vol. 35 Issue: 1 p285-297, 13p
- Subject
- Language
- ISSN
- 09607404